Table 2 The comparison of clinical characteristic between MSD and non-MSD groups
From: Attention/memory complaint is correlated with motor speech disorder in Parkinson’s disease
MSD group | non-MSD group | P value | |
|---|---|---|---|
Hypertension (%) | |||
Yes | 172(68.80%) | 47(73.44%) | 0.471 |
No | 78(31.20%) | 17(26.56%) | |
Hyperlipidemia (%) | |||
Yes | 94 (37.60%) | 21(32.81%) | 0.478 |
No | 156(62.40%) | 43(67.19%) | |
Ischemic heart disease (%) | |||
Yes | 33(13.20%) | 5(7.81%) | 0.238 |
No | 217(86.80%) | 59(92.19%) | |
Diabetes mellitus (%) | |||
Yes | 38(15.20%) | 12(18.75%) | 0.489 |
No | 212(84.80%) | 52(81.25%) | |
Lesion in frontal lobe (%) | |||
Yes | 195(78.00%) | 38(59.38%) | 0.002* |
No | 55(22.00%) | 26(40.62%) | |
Lesion in temporal lobe (%) | |||
Yes | 129(51.60%) | 23(35.94%) | 0.025* |
No | 121(48.40%) | 41(64.06%) | |
Lesion in parietal lobe (%) | |||
Yes | 2(0.80%) | 1(1.56%) | 0.576 |
No | 248(99.20%) | 63(98.44%) | |
Lesion in occipital lobe (%) | |||
Yes | 1(0.40%) | 1(1.56%) | 0.297 |
No | 249(99.60%) | 63(98.44%) | |
Concurrent dysphagia (%) | |||
Yes | 116(46.40%) | 20(31.25%) | 0.029* |
No | 134(53.60%) | 44(68.75%) | |
Concurrent other CNS diseases (%) | |||
Yes | 54(21.60%) | 18(28.13%) | 0.268 |
No | 196(78.40%) | 46(71.87%) | |
Tremor dominant forms (%) | |||
Yes | 173(69.20%) | 41(64.06%) | 0.431 |
No | 77(30.80%) | 23(35.94%) | |
Levodopa medication (%) | |||
Yes | 235(94.00%) | 58(90.63%) | 0.335 |
No | 15(6.00%) | 6(9.37%) | |
Dopamine agonist medication (%) | |||
Yes | 237(94.80%) | 62(96.88%) | 0.487 |
No | 13(5.20%) | 2(3.12%) | |
Selegiline medication (%) | |||
Yes | 167(66.80%) | 39(60.94%) | 0.378 |
No | 83(33.20%) | 25(39.06%) | |
Amantadine medication (%) | |||
Yes | 228(91.20%) | 56(87.50%) | 0.369 |
No | 22(8.80%) | 8(12.50%) | |
Levodopa equivalent dose (mg) | 396.60 | 384.40 | 0.557 |